{
    "ticker": "RGNX",
    "name": "Regenxbio Inc.",
    "description": "Regenxbio Inc. is a biotechnology company focused on the development and commercialization of gene therapies for the treatment of various diseases. Founded in 2014 and headquartered in Rockville, Maryland, Regenxbio utilizes its proprietary AAV (adeno-associated virus) technology platform to develop innovative treatments that address a broad range of genetic disorders and diseases. The company's lead product candidate, RGX-314, is designed to treat wet age-related macular degeneration (wet AMD) and has shown promising results in clinical trials. Regenxbio is also exploring other therapeutic areas, including neurological disorders and hemophilia, through its growing pipeline of gene therapy candidates. The company aims to unlock the full potential of gene therapy to provide transformative and durable solutions for patients. With a commitment to scientific excellence and patient-centric development, Regenxbio continues to advance its mission of transforming the lives of patients through innovative genomic medicine.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Rockville, Maryland, USA",
    "founded": "2014",
    "website": "https://www.regenxbio.com",
    "ceo": "Kenneth D. Mills",
    "social_media": {
        "twitter": "https://twitter.com/regenxbio",
        "linkedin": "https://www.linkedin.com/company/regenxbio/"
    },
    "investor_relations": "https://investors.regenxbio.com",
    "key_executives": [
        {
            "name": "Kenneth D. Mills",
            "position": "CEO"
        },
        {
            "name": "Debbie A. B. O'Connor",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gene Therapies",
            "products": [
                "RGX-314",
                "RGX-121",
                "RGX-111"
            ]
        }
    ],
    "seo": {
        "meta_title": "Regenxbio Inc. | Innovative Gene Therapies",
        "meta_description": "Explore Regenxbio Inc., a leader in biotechnology developing gene therapies for various diseases. Learn about their innovative AAV technology and product pipeline.",
        "keywords": [
            "Regenxbio",
            "Gene Therapy",
            "Biotechnology",
            "AAV Technology",
            "RGX-314",
            "Wet AMD"
        ]
    },
    "faq": [
        {
            "question": "What is Regenxbio known for?",
            "answer": "Regenxbio is known for its development of gene therapies using its proprietary AAV technology platform."
        },
        {
            "question": "Who is the CEO of Regenxbio?",
            "answer": "Kenneth D. Mills is the CEO of Regenxbio Inc."
        },
        {
            "question": "Where is Regenxbio headquartered?",
            "answer": "Regenxbio is headquartered in Rockville, Maryland, USA."
        },
        {
            "question": "What are Regenxbio's main products?",
            "answer": "Regenxbio's main products include RGX-314, RGX-121, and RGX-111."
        },
        {
            "question": "When was Regenxbio founded?",
            "answer": "Regenxbio was founded in 2014."
        }
    ],
    "competitors": [
        "ADVM",
        "SABR",
        "SGMO",
        "AVTX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "BMY"
    ]
}